Effect of the phosphate binder sucroferric oxyhydroxide in dialysis patients on endogenous calciprotein particles, inflammation, and vascular cells.

"CONFLICT OF INTEREST STATEMENT D.C. has received research funding from Vifor Pharma and speaker's honoraria, travel support and research funding from Amgen, Astellas, AstraZeneca, Bayer, Chiesi, Medice, Novartis, Sandoz, Takeda, UCB and Vifor Pharma and holds advisory board positions at Alnylam, Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Chiesi, Gedeon Richter, Stada, Takeda, UCB and Vifor Pharma. S.G.H. has received research funding and travel support from Amgen and AstraZeneca. A.P. is an inventor of the T50 test and holds a patent on it. He is president of the board of directors, a part-time employee and stockholder of Calciscon AG, Nidau, Switzerland, which commercialises the T50 test. E.R.S has received research funding from the Royal Melbourne Hospital Project Grant, Amgen and Sanofi and holds stock in Calciscon AG. U.T. reports a research grant from the Medical Society of Upper Austria and received travel support from AstraZeneca, Baxter, Sandoz and Vifor Pharma. N.D.T. has received speaker's honoraria from Amgen, Shire and Takeda and travel support from Amgen, Shire, Takeda and Sanofi. M.C.H. and T.D.H. declare no relevant conflicts of interest. The results presented in this article have not been published previously in whole or part, except in abstract format."

"FUNDING The SO interventional study was an investigator-initiated study that was financially supported by Vifor Fresenius Medical Care Renal Pharma (Vifor Pharma), St. Gallen, Switzerland. Vifor Pharma had no role in the study design, data collection, data interpretation or preparation of the manuscript. The secondary analyses of this study were supported by a research grant of the Medical Society of Upper Austria (awarded to U.T.). E.R.S. was supported by a Viertel Charitable Foundation Clinical Investigator grant and Royal Melbourne Hospital Project grant (PG-004-2018)."

"The study was approved by the local ethics committee (A-VIII-16) and registered at the European Union clinical trials register (EudraCT 2016-004789-24) and ClinicalTrials.gov (NCT03010072)."